Equal efficacy of a generic piperacillin/tazobactam formulation: Results of a local screening protocol

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 3, 2011, Pages 286-287

  Sutter, Sarah Tschudin ^a   Widmer, Andreas Franz ^a   Frei, Reno ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

BROTH DILUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; ESCHERICHIA COLI; IN VITRO STUDY; LETTER; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; DRUGS, GENERIC; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 79951877213     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.006     Document Type: Letter

References (9)

1. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eighth edition. Approved standard M07-A8 2009, CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, 20th edn. Approved standard M100-S20 2010, CLSI, Wayne, PA.
3. Fujimura S., Fuse K., Takane H., Nakano Y., Gomi K., Kikuchi T., Watanabe A. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus. J. Infect. Chemother. 2010, [Epub ahead of print].
4. Gardner C.R., Walsh C.T., Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 2004, 3:926-934.
5. Jones R.N., Fritsche T.R., Moet G.J. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. Diagn. Microbiol. Infect. Dis. 2008, 61:76-79.
6. Moet G.J., Watters A.A., Sader H.S., Jones R.N. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagn. Microbiol. Infect. Dis. 2009, 65:319-322.
7. Vesga O., Agudelo M., Salazar B.E., Rodriguez C.A., Zuluaga A.F. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents. Chemother. 2010, 54:3271-3279.
8. WHO/DMP/RGS Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. World Health Organization, Geneva, Switzerland 1998, Available at:, Accessed November 7, 2010. http://apps.who.int/prequal/info_general/documents/WHO_DMP_RGS_98_5_R.pdf.
9. Ye Y, Lee J, Chen Y, Lin SW, Chien S (2006). A comparative study of the clinical efficacy of two piperacillin/tazobactam products. Annual Conference of Taiwan Society of Health System Pharmacists. Taiwan. Poster 27.